Cycle Pharmaceuticals signs partnership with Catalent to develop its rare disease drugs
Cycle Pharmaceuticals, the Cambridge pharma company, is to work with Catalent Inc to develop four of its drug products for rare diseases.
New Jersey-based Catalent’s technology will be applied to Cycle’s products for rare metabolic and neurological disorders.
Catalent’s Zydis oral disintegrating tablet (ODT) has known advantages over conventional oral dosage forms, with improved patient compliance, adherence and convenience.
And its Zydis Ultra platform - the next generation ODT technology - enables increased drug load and better taste masking.
Antonio Benedetti, CEO of Cycle, based at The Barrett Building in Little St Mary's Lane, said: “Cycle’s core area of expertise is to improve rare disease medicines in order to make life easier for patients of all ages.
“These drug products will benefit patients with a broad range of unmet needs.
“Zydis technology has consistently proven its effectiveness in overcoming challenges faced by patients, such as swallowing difficulties and large pill burdens.
“Working in partnership with Catalent to apply the Zydis technology to Cycle’s product pipeline will be life-changing for both patients and their caregivers.”
Jonathan Arnold, president of Catalent’s oral drug delivery business, added: “Catalent has proven experience and expertise in drug formulation and working with partners to bring new therapies to market quickly.
“The Zydis technology platform has been shown to be very versatile and effective in developing easy-to-administer dose forms for innovators, and having evaluated Cycle’s molecules at our Swindon facility, we believe them to be excellent candidates for further development.”
Cycle, which also has US offices in Boston, Massachusetts, is focused on improving orphan drugs to treat rare diseases, repurposing drugs and reinstating generic drugs previously available in the market.
Catalent is a global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
More by this authorPaul Brackley
This website and its associated newspaper are members of the Independent Press Standards Organisation (IPSO)